Four blocked mutants of aclacinomycin-producing Streptomyces galilaeus MA144-M1 produced new anthracyclinones; 2-hydroxyaklavinone, its non-esterified analog and 2-hydroxy-7-deoxyaklavinone, several new anthracyclines; 2-deoxyfucosyl-2-deoxyfucosyl-rhodosaminylaklavinone (MA144 U1), 2-deoxyfucosyl-rhodosaminylaklavinone (MA144 U2) and five aklavinone glycosides devoid of amino sugar, designated as MA144 U5, U6, U7, U8 and U9.
No takes yet. Share an insight, caveat, or question.
Matsuzawa et al. (1981) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: